Methadone maintenance treatment for heroin addiction (Dole and Nyswander)

Heroin addiction in the 1960s was treated almost entirely through detoxification and abstinence programs. Pharmacologic maintenance was not part of the therapeutic vocabulary. Vincent Dole, a physician at the Rockefeller Institute who had studied obesity and metabolism, was joined in 1964 by the psychiatrist Marie Nyswander and the young internist Mary Jeanne Kreek. Dole proposed that addiction was an illness, a metabolic disease with behavioral manifestations, which abstinence alone could not reverse.

The team began studies with heroin addicts at the Rockefeller Hospital in early 1964 and within six months had worked out how methadone could be used for maintenance: a long-acting opioid taken by mouth once a day that relieved craving and, at adequate doses, blocked the effect of heroin, which they later called narcotic blockade. By 1965, when they published in JAMA, the trial had grown to 22 patients.

The framing Dole and Nyswander chose was as deliberate as the clinical design. They described heroin addiction explicitly as a metabolic disease, not a character defect, and compared methadone to insulin in diabetes: in their view it corrected an underlying dysfunction, while critics said it substituted one addiction for another. That framing was controversial. Abstinence-based programs and law enforcement agencies objected that maintenance simply sustained dependence, and moral objections to prescribing opioids to addicts ran deep in both medicine and policy.

Federal rules came gradually. The FDA issued regulations for methadone programs in 1972 and approved methadone for long-term treatment of opiate addiction in 1973, and the Narcotic Addict Treatment Act of 1974 confined methadone dispensing to licensed programs. Methadone maintenance is now provided to about one million people worldwide.

Buprenorphine, a partial opioid agonist, was approved by the FDA in October 2002 for office-based treatment, and for the first time since the 1910s American doctors in ordinary practice could treat opioid addiction with an opioid medication. Methadone kept its role for patients with more severe dependence or prior treatment failure but stayed confined to clinics. In 2023, after the Mainstreaming Addiction Treatment Act of 2022, the special federal waiver doctors had needed to prescribe buprenorphine was eliminated.